Article
A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders.
La Clinica terapeutica - 1 Jan 2012
Hamidah N H, Farisah N R, Azlinda A B, Wong F L, Das S, Fadillah S A W, Ainoon O
Abstract excerpt
BACKGROUND AND AIMS: Chronic myeloproliferative diseases (MPDs) are heterogenous group of haematological malignant disorders. It is now a well recognized fact that the JAK2 (V617F) mutation occurs in majority of the patients with polycythaemia vera (PV) and half of those with myelofibrosis and essential thrombocythaemia. The presence of JAK2 (V617F) mutation is considered an important criterion for the exclusion...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.